256 Newsroom — Uganda's Digital News Infrastructure
Health

CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial - Nature

Published by Nature.com 27 August 2026 at 13:07
Share
CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial - Nature
Image · Nature.com

What the report says

In the phase 1 part of the ongoing phase 1/2 COMPARE trial, CD19 CAR T cell treatment of patients with severe, treatment-refractory rheumatoid arthritis was well tolerated with clinical improvement seen in all patients.

Read the full report at Nature.com →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

More stories by this journalist

Other publications from this journalist — open any story without leaving the article page.

No other published stories from this publisher yet.

Related reporting

Uganda Urged to Decriminalise Suicide as Advocates Push for Mental Health ReformNile Post 256 Newsroom Staff shortage, grounded ambulances dominate Lango health assembly findings - Daily MonitorDaily Monitor UCI Rebrands as Uganda Strengthens Capacity for Advanced Cancer CareNile Post 256 Newsroom Health Ministry warns of HIV prevention complacency - monitor.co.ugDaily Monitor Parliamentary Health Committee Flags Staffing, Equipment Gaps in Busoga HospitalsNile Post Rukungiri Health Workers Urged to Keep Professional Licences Up to DateNile Post